异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹

行情直击09-17

9月17日，维立志博-B盘中上涨5.55%，报57.1港元/股，成交额5255.85万港元。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型"利好兑现"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持"跑赢大市"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1144405437?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-17 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144405437","market":"us","top_or_hot":-1,"title":"异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹","media":"行情直击","content":"<p><p>9月17日，维立志博-B盘中上涨5.55%，报57.1港元/股，成交额5255.85万港元。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型\"利好兑现\"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持\"跑赢大市\"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-17 10:05 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月17日，维立志博-B盘中上涨5.55%，报57.1港元/股，成交额5255.85万港元。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1144405437","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144405437","pubTimestamp":1789610758,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型\"利好兑现\"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持\"跑赢大市\"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Analysis of Unusual Movements | Weili Zhibo-B rose 5.55% intraday, rebounding after two consecutive days of pullback following the release of WCLC data.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"9月17日，维立志博-B盘中上涨5.55%，报57.1港元/股，成交额5255.85万港元。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型\"利好兑现\"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持\"跑赢大市\"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144405437","isCrawlerRequest":true}